Christian Klein,
Expert Scientist/Head
Christian Klein, Distinguished Scientist is Head of Oncology Programs and Head of the Tumor Immunology Group at the Roche Innovation Center Zurich, Roche Pharmaceutical Research and Early Development, Switzerland specialized in the discovery, validation and preclinical development of antibody based Cancer Immunotherapy (CIT) and bispecific antibodies. During his >14 years at Roche he has made major contributions as research project leader to the development and FDA/EMA approval of GAZYVA/GAZYVARO (obinutuzumab, GA101), to the preclinical development of four bispecific antibodies currently in active clinical development: 1) anti-Ang-2/VEGF CrossMAb RG7221 (vanucizumab) in oncology (Ph II), 2) anti-VEGF/Ang-2 CrossMAb RG7716 in ophthalmology (Ph I), 3) CEA-IL2v immunocytokine RG7813 (Ph I), 4) CEA-CD3 T cell bispecific antibody (CEA TCB) RG7802 (Ph I), and lead the development of Roche’s novel bispecific antibody technologies e.g. the CrossMAb, immunocytokine and T cell bispecific antibody platforms.
|
|
|
